Investigational drug · Phase 2
ACE-86225106
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ACE-86225106"
First trial start
2024
Mar 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACE-86225106", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor, Adult
- BRCA1 Mutation
- BRCA2 Mutation
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Ovarian cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ACE-86225106" as an intervention, largest first.
- Study of ACE-86225106 to Treat Patients With Advanced Solid TumorsActive, not recruiting
Acerand Therapeutics (Shanghai) LimitedIndustry
NCT06380660 · 298 participants (planned) · Start Mar 22, 2024 · Primary completion Dec 21, 2028
Drug: ACE-86225106 tablet · For: Solid Tumor, Adult; BRCA1 Mutation; BRCA2 Mutation and 3 more
Sites: Chongqing, China; Fuzhou, China; Guangzhou, China · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor, Adult
- VisugromabCTL-002, Visugromab RDEPhase 36 trials
CatalYm GmbH · Adult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Unresectable or Metastatic Hepatocellular Carcinoma
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- CRB-701Phase 32 trials
Corbus Pharmaceuticals Inc. · Solid Tumor, Adult, Oropharyngeal Carcinoma (OPC)
- HMPL-453Phase 32 trials
Hutchmed · Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult, Solid Tumor
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- VS-7375Phase 24 trials
Verastem, Inc. · G12D Mutated KRAS, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials
A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.